Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Immunome presented additional Phase 3 RINGSIDE data for varegacestat in progressing desmoid tumors at ESMO 2026, including a rapid oral presentation on patient-reported outcomes. At week 48, varegacestat improved symptom burden (GODDESS TSS-5 least-squares mean change of -1.50 vs +0.59 for placebo) and physical function (PROMIS +3.90 vs -3.04), building on the previously reported positive primary and key secondary endpoints.
Key figures
- Drug Name
- varegacestat
- Phase Of Trial
- Phase 3
- Orr placebo
- 9%
- Orr varegacestat
- 56%
- Pfs hazard ratio
- 0.16
- Patients randomized
- 156
- Progression risk reduction
- 84%
- Goddess tss5 change placebo
- 0.59
- Goddess tss5 change varegacestat
- -1.5
- Promis physical function change placebo
- -3.04
- Promis physical function change varegacestat
- 3.9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.